MXCT
MaxCyte, Inc.NASDAQHealthcare$0.75+0.74%ClosedMarket Cap: $80.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.44
P/S
2.31
EV/EBITDA
-1.81
DCF Value
$-3.49
FCF Yield
-47.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.4%
Operating Margin
-131.9%
Net Margin
-135.1%
ROE
-24.1%
ROA
-22.0%
ROIC
-23.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $7.3M | 5.3% | $-6.5M | $-9.6M | $-0.09 | — |
| FY 2025 | $33.0M | 68.4% | $-43.5M | $-44.6M | $-0.42 | — |
| Q3 2025 | $6.8M | 92.4% | $-10.6M | $-12.4M | $-0.12 | — |
| Q2 2025 | $8.5M | 82.1% | $-14.2M | $-12.4M | $-0.12 | — |
| Q1 2025 | $10.4M | 85.6% | $-12.3M | $-10.3M | $-0.10 | — |
| Q4 2024 | $8.7M | 73.8% | $-12.9M | $-10.6M | $-0.10 | — |
| FY 2024 | $38.6M | 81.6% | $-51.2M | $-41.1M | $-0.39 | — |
| Q3 2024 | $8.2M | 76.4% | $-14.1M | $-11.6M | $-0.11 | — |
| Q2 2024 | $10.4M | 85.7% | $-12.0M | $-9.4M | $-0.09 | — |
| Q1 2024 | $11.3M | 87.6% | $-12.3M | $-9.5M | $-0.09 | — |
| Q4 2023 | $15.7M | 90.0% | $-8.1M | $-5.3M | $-0.05 | — |
| FY 2023 | $41.3M | 88.5% | $-48.3M | $-37.9M | $-0.37 | — |